全文获取类型
收费全文 | 27326篇 |
免费 | 2910篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 340篇 |
儿科学 | 868篇 |
妇产科学 | 524篇 |
基础医学 | 3608篇 |
口腔科学 | 573篇 |
临床医学 | 3282篇 |
内科学 | 4797篇 |
皮肤病学 | 255篇 |
神经病学 | 2915篇 |
特种医学 | 1012篇 |
外科学 | 4327篇 |
综合类 | 700篇 |
一般理论 | 5篇 |
预防医学 | 3009篇 |
眼科学 | 522篇 |
药学 | 1691篇 |
中国医学 | 17篇 |
肿瘤学 | 1836篇 |
出版年
2021年 | 362篇 |
2020年 | 221篇 |
2019年 | 402篇 |
2018年 | 521篇 |
2017年 | 381篇 |
2016年 | 377篇 |
2015年 | 445篇 |
2014年 | 608篇 |
2013年 | 1003篇 |
2012年 | 1342篇 |
2011年 | 1295篇 |
2010年 | 746篇 |
2009年 | 731篇 |
2008年 | 1219篇 |
2007年 | 1186篇 |
2006年 | 1154篇 |
2005年 | 1066篇 |
2004年 | 1104篇 |
2003年 | 1050篇 |
2002年 | 903篇 |
2001年 | 900篇 |
2000年 | 927篇 |
1999年 | 742篇 |
1998年 | 371篇 |
1997年 | 320篇 |
1996年 | 340篇 |
1995年 | 319篇 |
1994年 | 268篇 |
1993年 | 312篇 |
1992年 | 652篇 |
1991年 | 637篇 |
1990年 | 608篇 |
1989年 | 610篇 |
1988年 | 582篇 |
1987年 | 601篇 |
1986年 | 527篇 |
1985年 | 526篇 |
1984年 | 403篇 |
1983年 | 357篇 |
1982年 | 236篇 |
1981年 | 218篇 |
1980年 | 206篇 |
1979年 | 363篇 |
1978年 | 202篇 |
1977年 | 209篇 |
1976年 | 231篇 |
1975年 | 184篇 |
1974年 | 240篇 |
1973年 | 228篇 |
1972年 | 187篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Patrick L. Wagner MD Frances Austin MD Ugwuji Maduekwe MD Arun Mavanur MD Lekshmi Ramalingam MD Heather L. Jones PA Matthew P. Holtzman MD Steven A. Ahrendt MD Amer H. Zureikat MD James F. Pingpank MD Herbert J. Zeh MD David L. Bartlett MD Haroon A. Choudry MD 《Annals of surgical oncology》2013,20(4):1056-1062
Background
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) are frequently used to treat appendiceal carcinomatosis. Some patients require multivisceral resection because of the volume of disease. It is unclear whether extent of CRS impacts survival in appendiceal carcinomatosis.Methods
We analyzed 282 patients undergoing attempted CRS/HIPEC for appendiceal carcinomatosis. Patients were defined as having undergone Extensive CRS (n = 60) if they had >3 organ resections or >2 anastomoses; a subgroup of Extreme CRS patients (n = 10) had ≥5 organ resections and ≥3 anastomoses. Kaplan–Meier survival curves and multivariate Cox-regression models were used to identify prognostic factors affecting outcomes.Results
Relative to the comparison group, patients undergoing Extensive CRS had a higher median peritoneal carcinomatosis index, operative duration, blood loss, and length of stay. No difference in completeness of cytoreduction, severe morbidity, or 60-day mortality was evident. Subgroup analysis of 10 patients undergoing extreme CRS likewise revealed no increase in severe morbidity or mortality. Median progression-free (PFS) and overall survival (OS) were 23.5 and 74 months in the comparison group; 18.5 (p = 0.086) and 51 (p = 0.85) months in the Extensive CRS group; and 40 months and not reached in the Extreme CRS subgroup. In a multivariable analysis, extent of CRS was not independently associated with PFS or OS.Conclusions
Extensive CRS is associated with greater OR time, blood loss, and length of stay, but is not associated with higher morbidity, mortality, or inferior oncologic outcomes in patients with appendiceal carcinomatosis. 相似文献992.
April Saval PA 《The journal of spinal cord medicine》2013,36(4):394-397
Background/Objective: Intrathecal baclofen (ITB) has been shown to be an effective treatment for severe spasticity of spinal or cerebral origin. Although most patients respond well to an ITB trial, there are often difficulties in achieving and/or maintaining such effectiveness with ITB pump treatment. There are few published guidelines for dosing efficacy and no studies looking at the effect of concentration of ITB on spasticity management.Methods: Case series of 3 adults with severe spasticity treated with ITB pump: a 44-year-old man with C7 tetraplegia using a 40-mL Medtronic SynchroMed II pump with 500-μg/mL concentration; a 35-year-old woman with traumatic brain injury with right spastic hemiplegia using a 18-mL Medtronic SynchroMed EL pump with 2,000-μg/mL concentration; and a 43-year-old woman with spastic diplegic cerebral palsy using a 40-mL Medtronic SynchroMed II pump with 2,000-μg/mL concentration.Results: After reducing ITB concentrations in the pump, either as part of a standard protocol for dye study to assess the integrity of pump and catheter system or secondary to plateau in therapeutic efficacy, patients experienced temporary, significant reduction in spasticity based on range of motion, Modified Ashworth scores, and verbal feedback.Conclusions: Decreasing the concentration of ITB seems to affect spasticity control. Further research in this area is needed for those patients with refractory spasticity to optimize efficacy of ITB therapy. 相似文献
993.
Scott Worley MD BScPT Jeff Pike MD David Anderson MD Jo-Anne Douglas BSc Kara Thompson BSc MSc 《The journal of spinal cord medicine》2013,36(4):379-387
Background: When venous thromboembolism (VTE) includes deep-vein thrombosis (DVT) and pulmonary embolism (PE), patients with acute traumatic spinal cord injury (SCI) have the highest incidence of VTE among all hospitalized groups, with PE the third most common cause of death. Although low-molecular-weight heparin (LMWH) outperforms low-dose unfractionated heparin (LDUH) in other patient populations, the evidence in SCI remains less robust.Objective: To determine whether the efficacy for LMWH shown in previous SCI surveillance studies (eg, routine Doppler ultrasound) would translate into real-world effectiveness in which only clinically evident VTE is investigated (ie, after symptoms or signs present).Methods: A retrospective cohort study was conducted of 90 patients receiving LMWH dalteparin (5,000 U daily) or LDUH (5,000 U twice daily) for VTE prophylaxis after acute traumatic SCI. The incidence of radiographically confirmed VTE was primarily analyzed, and secondary outcomes included complications of bleeding and heparin-induced thrombocytopenia.Results: There was no statistically significant association (p = 0.7054) between the incidence of VTE (7.78% overall) and the type of prophylaxis received (LDUH 3/47 vs dalteparin 4/43). There was no significant differences in complications, location of VTE, and incidence of fatal PE. Paraplegia (as opposed to tetraplegia) was the only risk factor identified for VTE.Conclusions: There continues to be an absence of definitive evidence for dalteparin (or other LMWH) over LDUH as the choice for VTE prophylaxis in patients with SCI. Novel approaches to VTE prophylaxis are urgently required for this population, whose risk of fatal PE has not decreased over the last 25 years. 相似文献
994.
995.
996.
997.
998.
999.
1000.